U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H26N2O6
Molecular Weight 426.4623
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PANAMESINE

SMILES

COC1=CC=C(C=C1)N2C[C@H](CN3CCC(O)(CC3)C4=CC=C5OCOC5=C4)OC2=O

InChI

InChIKey=NINYZUDVKTUKIA-IBGZPJMESA-N
InChI=1S/C23H26N2O6/c1-28-18-5-3-17(4-6-18)25-14-19(31-22(25)26)13-24-10-8-23(27,9-11-24)16-2-7-20-21(12-16)30-15-29-20/h2-7,12,19,27H,8-11,13-15H2,1H3/t19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H26N2O6
Molecular Weight 426.4623
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Panamesine (also known as EMD 57445) was studied as a sigma receptor ligand alleged to have antipsychotic effects. Panamesine reached phase II clinical trials for schizophrenia before the discontinuation of its development.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
In a treatment period of 4 weeks, 12 patients received EMD 57445 up to 60 mg/day for 4 weeks.
Route of Administration: Oral
Substance Class Chemical
Record UNII
023D9E916L
Record Status Validated (UNII)
Record Version